 |
|
|
| |
Abbott/Enanta - Potent HCV Protease Inhibitors with the Potential for Once-daily Dosing and Broad Genotype Coverage
|
| |
| |
EASL
Reported by Jules Levin
L. J. Jiang, Y. Gai, T. Middleton*, K. Kurtz*, L. Lu*, S. Liu, T. Phan, X. Luo, T. Poon, B. Brasher, K. McDaniel*, D. Kempf* and Y. S. Or
Enanta Pharmaceuticals, Inc.
*Abbott Laboratories
From Jules: Abbott has an ambitious HCV drug program that includes polymerase inibitors and protease inhibitors. The Abbott/Enanta protease inhibitor preclinical data presented at EASL show them to be potent and with potential capacity to reach high levels. The data finds the PIs to be active against key HCV mutations suggesting perhaps antiviral activity against HCV resistance to other protease inhibitors, but of course this would have to be established in patients but would of particular appeal.
|
| |
|
|
|
|
|
